Regeneron Pharmaceuticals, Inc.
cemdisiran
myasthenia gravis
Resolved
7days ago
Catalyst readout · ~ Jun 30, 2026 estimated
What's at stake
A key catalyst for cemdisiran (myasthenia gravis) is expected ~ Jun 30, 2026.
Primary source
· SEC 8-K
verified 14h ago
“The Company submitted a New Drug Application (NDA) for cemdisiran (C5 siRNA therapy) in myasthenia gravis, and utilized an FDA Rare Pediatric Disease Priority Review Voucher.”